Man Group plc Makes New $6.51 Million Investment in Ultragenyx Pharmaceutical Inc. $RARE

Man Group plc purchased a new stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) in the second quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 195,110 shares of the biopharmaceutical company’s stock, valued at approximately $6,515,000. Man Group plc owned approximately 0.20% of Ultragenyx Pharmaceutical at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. BlackRock Inc. bought a new stake in shares of Ultragenyx Pharmaceutical during the second quarter worth $355,746,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in shares of Ultragenyx Pharmaceutical in the 2nd quarter valued at $6,397,000. Deutsche Bank AG acquired a new stake in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at $5,503,000. Blue Owl Capital Holdings LP bought a new stake in Ultragenyx Pharmaceutical during the 2nd quarter worth $6,098,000. Finally, Ieq Capital LLC bought a new stake in Ultragenyx Pharmaceutical during the 2nd quarter worth $3,540,000. Institutional investors and hedge funds own 97.67% of the company’s stock.

Insider Buying and Selling

In related news, CFO Howard Horn sold 4,653 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Monday, June 1st. The shares were sold at an average price of $23.77, for a total value of $110,601.81. Following the completion of the transaction, the chief financial officer directly owned 105,689 shares in the company, valued at approximately $2,512,227.53. The trade was a 4.22% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Karah Herdman Parschauer sold 1,899 shares of the company’s stock in a transaction dated Monday, June 15th. The shares were sold at an average price of $24.62, for a total value of $46,753.38. Following the sale, the executive vice president owned 94,462 shares in the company, valued at approximately $2,325,654.44. This represents a 1.97% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 8,552 shares of company stock valued at $207,455. 5.20% of the stock is owned by insiders.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ RARE opened at $25.61 on Friday. Ultragenyx Pharmaceutical Inc. has a fifty-two week low of $18.29 and a fifty-two week high of $39.89. The stock has a market cap of $2.52 billion, a price-to-earnings ratio of -4.39 and a beta of 0.35. The firm’s 50-day simple moving average is $28.55 and its 200 day simple moving average is $25.03.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last posted its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative net margin of 81.79% and a negative return on equity of 1,024.42%. The firm had revenue of $214.00 million for the quarter, compared to the consensus estimate of $183.08 million. During the same period in the previous year, the firm earned ($1.17) EPS. The business’s revenue for the quarter was up 28.5% compared to the same quarter last year. On average, sell-side analysts predict that Ultragenyx Pharmaceutical Inc. will post -3.97 EPS for the current year.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on the stock. Weiss Ratings upgraded shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 9th. Cantor Fitzgerald increased their price objective on Ultragenyx Pharmaceutical from $96.00 to $103.00 and gave the company an “overweight” rating in a report on Thursday, August 20th. Royal Bank Of Canada raised their target price on Ultragenyx Pharmaceutical from $35.00 to $40.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Wedbush cut their target price on Ultragenyx Pharmaceutical from $27.00 to $26.00 and set a “neutral” rating on the stock in a report on Wednesday, May 6th. Finally, Guggenheim reduced their price target on Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, fifteen have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $59.44.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.